Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis

Journal of Immunology

Volumn 184, Issue 4, 2010, Pages 2183-2193

  Wu, Tianfu ^a   Fu, Yuyang ^a   Brekken, Deirdre ^a   Yan, Mei ^a   Zhou, Xin J ^a   Vanarsa, Kamala ^a   Deljavan, Nima ^a   Ahn, Chul ^a   Putterman, Chaim ^b   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; ALPHA FETOPROTEIN; ANGIOSTATIN; ANGIOTENSINOGEN; CARBOXYLESTERASE; CERULOPLASMIN; CHYMOSIN; CLUSTERIN; COMPLEMENT COMPONENT C3; CYTOCHROME P450; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; HAPTOGLOBIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEMOPEXIN; KALLIKREIN; PROSTAGLANDIN D SYNTHASE; PROTEIN; RENIN; SERUM ALBUMIN; SERUM AMYLOID P; SMAD4 PROTEIN; SUPEROXIDE DISMUTASE; THYROID PEROXIDASE; TRANSCRIPTION FACTOR SIX3; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VIMENTIN; ZINC FINGER PROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; ISOMERASE; LIPOCALIN; PEPTIDE HYDROLASE; PROSTAGLANDIN R2 D ISOMERASE; PROSTAGLANDIN R2 D-ISOMERASE; PROTEOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS BASEMENT MEMBRANE; KIDNEY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UREMIA; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CONGENIC STRAIN; DISEASE MODEL; ENZYMOLOGY; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; LONGITUDINAL STUDY; MOLECULAR GENETICS; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; UPREGULATION; URINE; VALIDATION STUDY;

AMINO ACID SEQUENCE; ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY; LIPOCALINS; LONGITUDINAL STUDIES; LUPUS NEPHRITIS; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PREDICTIVE VALUE OF TESTS; PROTEOME; SERUM AMYLOID P-COMPONENT; SUPEROXIDE DISMUTASE; UP-REGULATION;

EID: 77949895138     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900292     Document Type: Article

References (60)

1. Cameron, J. S. 1999. Lupus nephritis. J. Am. Soc. Nephrol. 10: 413-424.
2. Hahn, B. H. 1998. Antibodies to DNA. N. Engl. J. Med. 338: 1359-1368.
3. Ponticelli, C., and G. Moroni. 1998. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 7: 635-638.
4. Houssiau, F. A. 2004. Management of lupus nephritis: an update. J. Am. Soc. Nephrol. 15: 2694-2704.
5. Bertsias, G., and D. T. Boumpas. 2008. Update on the management of lupus nephritis: let the treatment fit the patient. Nat. Clin. Pract. Rheumatol. 4: 464-472.
6. Fiehn, C., Y. Hajjar, K. Mueller, R. Waldherr, A. D. Ho, and K. Andrassy. 2003. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann. Rheum. Dis. 62: 435-439.
7. Heinlen, L. D., M. T. McClain, J. Merrill, Y. W. Akbarali, C. C. Edgerton, J. B. Harley, and J. A. James. 2007. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 56: 2344-2351.
8. Rovin, B. H., D. J. Birmingham, H. N. Nagaraja, C. Y. Yu, and L. A. Hebert. 2007. Biomarker discovery in human SLE nephritis. Bull. NYU Hosp. Jt. Dis. 65: 187-193.
9. Christopher-Stine, L., M. Petri, B. C. Astor, and D. Fine. 2004. Urine protein-tocreatinine ratio is a reliable measure of proteinuria in lupus nephritis. J. Rheumatol. 31: 1557-1559. (Pubitemid 39006637)
10. Spronk, P. E., H. Bootsma, M. G. Huitema, P. C. Limburg, and C. G. Kallenberg. 1994. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin. Exp. Immunol. 97: 439-444.
11. Belmont, H. M., J. Buyon, R. Giorno, and S. Abramson. 1994. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum. 37: 376-383.
12. Manzi, S., J. S. Navratil, M. J. Ruffing, C. C. Liu, N. Danchenko, S. E. Nilson, S. Krishnaswami, D. E. King, A. H. Kao, and J. M. Ahearn. 2004. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum. 50: 3596-3604.
13. Nakamura, T., C. Ushiyama, S. Suzuki, M. Hara, N. Shimada, K. Sekizuka, I. Ebihara, and H. Koide. 2000. Urinary podocytes for the assessment of disease activity in lupus nephritis. Am. J. Med. Sci. 320: 112-116.
14. Chan, R. W., F. M. Lai, E. K. Li, L. S. Tam, T. Y. Wong, C. Y. Szeto, P. K. Li, and C. C. Szeto. 2004. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 50: 2882-2890.
15. Chan, R. W., L. S. Tam, E. K. Li, F. M. Lai, K. M. Chow, K. B. Lai, P. K. Li, and C. C. Szeto. 2003. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 48: 1326-1331.
16. Tucci, M., E. V. Barnes, E. S. Sobel, B. P. Croker, M. S. Segal, W. H. Reeves, and H. B. Richards. 2004. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 50: 1842-1849.
17. Rovin, B. H., H. Song, D. J. Birmingham, L. A. Hebert, C. Y. Yu, and H. N. Nagaraja. 2005. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16: 467-473.
18. Wu, T., C. Xie, M. Bhaskarabhatla, M. Yan, A. Leone, S. S. Chen, X. J. Zhou, C. Putterman, and C. Mohan. 2007. Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum. 56: 949-959.
19. Wu, T., C. Xie, H. W. Wang, X. J. Zhou, N. Schwartz, S. Calixto, M. Mackay, C. Aranow, C. Putterman, and C. Mohan. 2007. Elevated urinary VCAM-1, Pselectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 179: 7166-7175.
20. Molad, Y., E. Miroshnik, J. Sulkes, S. Pitlik, A. Weinberger, and Y. Monselise. 2002. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clin. Exp. Rheumatol. 20: 403-406.
21. Xie, C., R. Sharma, H. Wang, X. J. Zhou, and C. Mohan. 2004. Strain distribution pattern of susceptibility to immune-mediated nephritis. J. Immunol. 172: 5047-5055. (Pubitemid 38456432)
22. Fu, Y., Y. Du, and C. Mohan. 2007. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin. Immunol. 124: 109-118.
23. Fu, Y., C. Xie, J. Zhu, H. Zhou, J. Thomas, X. J. Zhou, and C. Mohan. 2006. Innate stimuli accentuate end-organ damage by nephrotoxic antibodies via Fc receptor and TLR stimulation and IL-1/TNF-a production. J. Immunol. 176: 632-639.
24. Cohen, P. L., and R. A. Eisenberg. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9: 243-269.
25. Mohan, C., L. Morel, P. Yang, H. Watanabe, B. Croker, G. Gilkeson, and E. K. Wakeland. 1999. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J. Clin. Invest. 103: 1685-1695.
26. Pizarro, S., J. Monárrez Espino, A. Ruiz, L. J. Jara, A. Nava, and C. Riebeling-Navarro. 2007. Soluble vascular cell adhesion molecule-1 indicates SLE disease activity and specific organ involvement. Rev. Alerg. Mex. 54: 189-195.
27. Li, Y., M. Tucci, S. Narain, E. V. Barnes, E. S. Sobel, M. S. Segal, and H. B. Richards. 2006. Urinary biomarkers in lupus nephritis. Autoimmun. Rev. 5: 383-388.
28. Negi, V. S., A. Aggarwal, R. Dayal, S. Naik, and R. Misra. 2000. Complement degradation product C3d in urine: marker of lupus nephritis. J. Rheumatol. 27: 380-383.
29. Lewis, R. A., N. A. Soter, P. T. Diamond, K. F. Austen, J. A. Oates, and L. J. Roberts, 2nd. 1982. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129: 1627-1631. (Pubitemid 12031103)
30. Urade, Y., M. Ujihara, Y. Horiguchi, K. Ikai, and O. Hayaishi. 1989. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J. Immunol. 143: 2982-2989.
31. Tanaka, K., K. Ogawa, K. Sugamura, M. Nakamura, S. Takano, and K. Nagata. 2000. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J. Immunol. 164: 2277-2280.
32. O'Sullivan, S., B. Dahlén, S. E. Dahlén, and M. Kumlin. 1996. Increased urinary excretion of the prostaglandin D2 metabolite 9α, 11b-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 98: 421-432.
33. Pettipher, R., T. T. Hansel, and R. Armer. 2007. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 6: 313-325.
34. Flower, R. J., E. A. Harvey, and W. P. Kingston. 1976. Inflammatory effects of prostaglandin D2 in rat and human skin. Br. J. Pharmacol. 56: 229-233.
35. Fujitani, Y., Y. Kanaoka, K. Aritake, N. Uodome, K. Okazaki-Hatake, and Y. Urade. 2002. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J. Immunol. 168: 443-449.
36. Ogawa, M., N. Hirawa, T. Tsuchida, N. Eguchi, Y. Kawabata, A. Numabe, H. Negoro, R. Hakamada-Taguchi, K. Seiki, S. Umemura, et al. 2006. Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats. Nephrol. Dial. Transplant. 21: 924-934.
37. Uehara, Y., H. Makino, K. Seiki, and Y. Urade. 2009. Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes: a cross-sectional and prospective multicentre study. Nephrol. Dial. Transplant. 24: 475-482.
38. Herlitz, H., A. Tarkowski, C. Svalander, R. Volkmann, and G. Westberg. 1988. Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice. Int. Arch. Allergy Appl. Immunol. 85: 272-277.
39. Tarkowski, A., H. Carlsten, H. Herlitz, and G. Westberg. 1990. Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease. Agents Actions 31: 96-101.
40. De Albuquerque, D. A., V. Saxena, D. E. Adams, G. P. Boivin, H. I. Brunner, D. P. Witte, and R. R. Singh. 2004. An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int. 65: 846-859.
41. Ikeda, T., D. Nakayama, T. Gomi, J. Sakurai, T. Yamazaki, and M. Yuhara. 1989. Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron 52: 72-75.
42. Daza, L., C. Kornhauser, L. Zamora, and J. Flores. 2005. Captopril effect on prostaglandin E2, thromboxane B2 and proteinuria in lupus nephritis patients. Prostaglandins Other Lipid Mediat. 78: 194-201.
43. Metsärinne, K. P., D. C. Nordström, Y. T. Konttinen, A. M. Teppo, and F. Y. Fyhrquist. 1992. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol. Int. 12: 93-96.
44. Lai, K. N., J. C. Leung, K. B. Lai, W. Y. To, V. T. Yeung, and F. M. Lai. 1998. Gene expression of the renin-angiotensin system in human kidney. J. Hypertens. 16: 91-102.
45. Dellalibera-Joviliano, R., M. L. Reis, and E. A. Donadi. 2001. Kinin system in lupus nephritis. Int. Immunopharmacol. 1: 1889-1896.
46. Kotajima, L., S. Aotsuka, M. Fujimani, M. Okawa-Takatsuji, M. Kinoshita, M. Sumiya, and K. Obata. 1998. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin. Exp. Rheumatol. 16: 409-415.
47. Urushihara, M., S. Kagami, T. Kuhara, T. Tamaki, and Y. Kuroda. 2002. Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol. Dial. Transplant. 17: 1189-1196.
48. Yunis, I., and A. S. Whitehead. 1990. The mouse C-reactive protein gene maps to distal chromosome 1 and, like its human counterpart, is closely linked to the serum amyloid P component gene. Immunogenetics 32: 361-363. (Pubitemid 20386295)
49. Pepys, M. B., and P. J. Butler. 1987. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem. Biophys. Res. Commun. 148: 308-313.
50. Butler, P. J., G. A. Tennent, and M. B. Pepys. 1990. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J. Exp. Med. 172: 13-18.
51. Hicks, P. S., L. Saunero-Nava, T. W. Du Clos, and C. Mold. 1992. Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol. 149: 3689-3694.
52. Mold, C., H. D. Gresham, and T. W. Du Clos. 2001. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine FcγRs. J. Immunol. 166: 1200-1205. (Pubitemid 32060280)
53. Connolly, K. M., V. J. Stecher, U. H. Rudofsky, and D. J. Pruden. 1988. Elevation of plasma fibronectin and serum amyloid P in autoimmune NZB, B/W, and MRL/1pr mice. Exp. Mol. Pathol. 49: 388-394.
54. Rodriguez, W., C. Mold, L. L. Marnell, J. Hutt, G. J. Silverman, D. Tran, and T. W. Du Clos. 2006. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum. 54: 325-335.
55. Bickerstaff, M. C., M. Botto, W. L. Hutchinson, J. Herbert, G. A. Tennent, A. Bybee, D. A. Mitchell, H. T. Cook, P. J. Butler, M. J. Walport, and M. B. Pepys. 1999. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5: 694-697.
56. Lee, S. S., S. Singh, K. Link, and M. Petri. 2008. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin. Arthritis Rheum. 38: 41-54.
57. Yasui, K., and A. Baba. 2006. Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. Inflamm. Res. 55: 359-363.
58. Melov, S., J. Ravenscroft, S. Malik, M. S. Gill, D. W. Walker, P. E. Clayton, D. C. Wallace, B. Malfroy, S. R. Doctrow, and G. J. Lithgow. 2000. Extension of life-span with superoxide dismutase/catalase mimetics. Science 289: 1567-1569.
59. Wang, J. S., L. P. Ger, and H. H. Tseng. 1997. Expression of glomerular antioxidant enzymes in human glomerulonephritis. Nephron 76: 32-38. (Pubitemid 27199036)
60. Taysi, S., M. Gul, R. A. Sari, F. Akcay, and N. Bakan. 2002. Serum oxidant/ antioxidant status of patients with systemic lupus erythematosus. Clin. Chem. Lab. Med. 40: 684-688.